Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial.

"Conflict of Interest Statement Stephen Lam Chan served as advisor for Astra-Zeneca, MSD, Eisai, and Ipsen and received research funding from Bayer, Eisai, Ipsen, SIRTEX, and MSD. Su Pin Choo has consulted for or received honorariums/fees from Astra-Zeneca, MSD, Eisai, Ipsen, BMS, Bayer, and Roche. David Tai has consulted for or received honorariums/fees from Novartis, MSD, Ipsen, Eisai, and BMS. Raghav Sundar has received honoraria from Bristol-Myers Squibb, Lilly, and MSD; has advisory activity with Bristol-Myers Squibb, Eisai, and AstraZeneca; received research funding from Paxman Coolers; and has received travel grants from AstraZeneca, Roche, and Taiho Pharmaceutical. All not related to submitted works. David C.E. Ng received funding from Sirtex, Bayer, MSD, and Novartis. Kelvin S.H. Loke has received honoraria from SIRTEX. Wei Peng Yong has consulted for or received honorariums/fees from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Novartis, MSD, Sanofi, and Taiho. Other authors have no conflicts of interest to declare."

"Funding Sources This study was funded by an independent research grant from SIRTEX Medical, Inc."